

Sylvant (siltuximab)

Override(s)	Approval Duration
Prior Authorization	1 year

Medications
Sylvant (siltuximab)

APPROVAL CRITERIA

Requests for Sylvant (siltuximab) may be approved if the following criteria are met:

- I. Individual has a diagnosis of Multicentric Castleman's Disease; **AND**
- II. Sylvant (siltuximab) is used as a single agent; **AND**
- III. Individual is human immunodeficiency virus negative; **AND**
- IV. Individual is human herpesvirus-8 negative;

OR

- V. Individual has a diagnosis of relapsed/refractory unicentric Castleman Disease (NCCN 2A); **AND**
- VI. Sylvant (siltuximab) used as a single agent; **AND**
- VII. Individual is Human immunodeficiency virus negative; **AND**
- VIII. Individual is Human herpes-8 negative; **AND**

OR

- IX. Individual has a diagnosis of Grade 4 chimeric antigen receptor (CAR) T cell-induced CRS (NCCN 2A); **AND**
- X. CRS is refractory to high-dose corticosteroids and other anti-IL-6 therapy.

Requests for Sylvant (siltuximab) may not be approved for the following:

- I. Individual has a current severe infection; **OR**
- II. When the above criteria are not met and for all other indications.

Key References:

1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: January 8, 2024.
2. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
3. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2024; Updated periodically.
4. NCCN Clinical Practice Guidelines in Oncology™. © 2024 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on January 8, 2024.
 - a. B-Cell Lymphomas. V6.2023. Revised October 10, 2023.
 - b. Management of Immunotherapy-related toxicities. V1.2024. Revised December 7, 2023.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.